US
CA
NZ
UK
AU
IND
Last update at 2025-07-14T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
Mon 26 May 25, 01:38 PMAstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
Wed 21 May 25, 01:05 PMTop Research Reports for Visa, AstraZeneca & Shell
Tue 20 May 25, 08:54 PMAstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks
Tue 20 May 25, 05:53 PMAstraZeneca says Airsupra reduced severe asthma risk by 47%
Tue 20 May 25, 04:20 PMAstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%
Tue 20 May 25, 12:06 AMTrump administration not backing down on Big Pharma pressure campaign
Sat 17 May 25, 01:30 PMAstraZeneca’s growth prospects are as attractive as ever. Keep buying
Wed 14 May 25, 06:19 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 2501.00M | -265.00000M | 3916.00M | 1548.00M | 1993.00M |
| Minority interest | -5.00000M | -3.00000M | 16.00M | 1469.00M | 1576.00M |
| Net income | 3288.00M | 112.00M | 3196.00M | 1335.00M | 2155.00M |
| Selling general administrative | 18955.00M | 15680.00M | 11693.00M | 12021.00M | 10362.00M |
| Selling and marketing expenses | 18955.00M | 15680.00M | 11693.00M | 11848.00M | 10362.00M |
| Gross profit | 31960.00M | 24980.00M | 21318.00M | 19463.00M | 17154.00M |
| Reconciled depreciation | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Ebit | 3847.00M | 1035.00M | 5222.00M | 3254.00M | 3412.00M |
| Ebitda | 9327.00M | 7565.00M | 8371.00M | 7016.00M | 7165.00M |
| Depreciation and amortization | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 3757.00M | 1056.00M | 5162.00M | 2924.00M | 3387.00M |
| Other operating expenses | 40594.00M | 36361.00M | 21455.00M | 21186.00M | 18703.00M |
| Interest expense | 1346.00M | 1300.00M | 1306.00M | 1432.00M | 1419.00M |
| Tax provision | -792.00000M | -380.00000M | 772.00M | 321.00M | -57.00000M |
| Interest income | 95.00M | 43.00M | 87.00M | 145.00M | 132.00M |
| Net interest income | -1251.00000M | -1257.00000M | -1219.00000M | -1237.00000M | -1228.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | -792.00000M | -380.00000M | 772.00M | 321.00M | -57.00000M |
| Total revenue | 44351.00M | 37417.00M | 26617.00M | 24384.00M | 22090.00M |
| Total operating expenses | 28203.00M | 23924.00M | 16156.00M | 16265.00M | 13767.00M |
| Cost of revenue | 12391.00M | 12437.00M | 5299.00M | 4921.00M | 4936.00M |
| Total other income expense net | -1256.00000M | -1321.00000M | -1246.00000M | -1376.00000M | -1394.00000M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 3293.00M | 115.00M | 3144.00M | 1227.00M | 2050.00M |
| Net income applicable to common shares | 3288.00M | 112.00M | 3196.00M | 1335.00M | 2155.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 96483.00M | 105363.00M | 66729.00M | 61377.00M | 60651.00M |
| Intangible assets | 39307.00M | 42387.00M | 20947.00M | 20833.00M | 21959.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 398.00M | 105.00M | 99.00M | 106.00M | 1240.00M |
| Total liab | 59425.00M | 66076.00M | 51091.00M | 46781.00M | 46607.00M |
| Total stockholder equity | 37037.00M | 39268.00M | 15622.00M | 13127.00M | 12468.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 1711.00M | 1763.00M | 2136.00M | 2120.00M | 1697.00M |
| Common stock | 387.00M | 387.00M | 328.00M | 328.00M | 317.00M |
| Capital stock | 387.00M | 387.00M | 328.00M | 328.00M | 317.00M |
| Retained earnings | -574.00000M | 1710.00M | 5299.00M | 2812.00M | 5683.00M |
| Other liab | 8499.00M | 13011.00M | 10491.00M | 10283.00M | 11114.00M |
| Good will | 19820.00M | 19997.00M | 11845.00M | 11668.00M | 11707.00M |
| Other assets | 4172.00M | 5302.00M | 4284.00M | 3466.00M | 2995.00M |
| Cash | 6166.00M | 6329.00M | 7832.00M | 5369.00M | 4831.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 26293.00M | 22594.00M | 20307.00M | 18117.00M | 16292.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 23066.00M | 24452.00M | 12548.00M | 12858.00M | 14282.00M |
| Short term debt | 5542.00M | 1893.00M | 2386.00M | 2010.00M | 1754.00M |
| Short long term debt | 5314.00M | 1660.00M | 2194.00M | 1822.00M | 1754.00M |
| Short long term debt total | 29232.00M | 30781.00M | 20380.00M | 18227.00M | 19113.00M |
| Other stockholder equity | 37224.00M | 37171.00M | 9995.00M | 9987.00M | 6468.00M |
| Property plant equipment | 9449.00M | 10171.00M | 8917.00M | 8335.00M | 7421.00M |
| Total current assets | 22593.00M | 26244.00M | 19544.00M | 15563.00M | 15591.00M |
| Long term investments | - | - | - | 1512.00M | 978.00M |
| Net tangible assets | -22090.00000M | -23116.00000M | -17170.00000M | -19374.00000M | -21198.00000M |
| Short term investments | 239.00M | 69.00M | 160.00M | 849.00M | 849.00M |
| Net receivables | 10521.00M | 10758.00M | 5651.00M | 5181.00M | 4837.00M |
| Long term debt | 22965.00M | 28134.00M | 17505.00M | 15730.00M | 17359.00M |
| Inventory | 4699.00M | 8983.00M | 4024.00M | 3193.00M | 2890.00M |
| Accounts payable | 19040.00M | 18938.00M | 15785.00M | 13987.00M | 12841.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 2296.00M | 2132.00M | 2102.00M | 3300.00M | 3042.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 73890.00M | 79119.00M | 47185.00M | 45814.00M | 45060.00M |
| Capital lease obligations | 953.00M | 987.00M | 681.00M | 675.00M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2960.00000M | 605.00M | 1999.00M | 125.00M | 140.00M |
| Change to liabilities | 1165.00M | 1405.00M | 1721.00M | 868.00M | -103.00000M |
| Total cashflows from investing activities | -2960.00000M | -11058.00000M | -285.00000M | -657.00000M | 963.00M |
| Net borrowings | -1441.00000M | 7654.00M | 1440.00M | -1702.00000M | 1473.00M |
| Total cash from financing activities | -6823.00000M | 3649.00M | -2203.00000M | -1765.00000M | -2044.00000M |
| Change to operating activities | - | 2021.00M | 2021.00M | 2021.00M | 2021.00M |
| Net income | 2501.00M | -265.00000M | 3916.00M | 1548.00M | 1993.00M |
| Change in cash | -55.00000M | -1508.00000M | 2323.00M | 552.00M | 1499.00M |
| Begin period cash flow | 6038.00M | 7546.00M | 5223.00M | 4671.00M | 3172.00M |
| End period cash flow | 5983.00M | 6038.00M | 7546.00M | 5223.00M | 4671.00M |
| Total cash from operating activities | 9808.00M | 5963.00M | 4799.00M | 2969.00M | 2618.00M |
| Issuance of capital stock | 29.00M | 29.00M | 30.00M | 3525.00M | 34.00M |
| Depreciation | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Other cashflows from investing activities | 60.00M | 54.00M | 87.00M | 274.00M | 193.00M |
| Dividends paid | -4364.00000M | -3856.00000M | -3572.00000M | -3592.00000M | 3484.00M |
| Change to inventory | 3941.00M | 1577.00M | -621.00000M | -316.00000M | -13.00000M |
| Change to account receivables | -1349.00000M | -961.00000M | -739.00000M | -898.00000M | -523.00000M |
| Sale purchase of stock | -920.00000M | 12413.00M | 3049.00M | 314.00M | 2971.00M |
| Other cashflows from financing activities | -297.00000M | 12235.00M | 2948.00M | 318.00M | 2904.00M |
| Change to netincome | -2491.00000M | -272.00000M | -1654.00000M | -802.00000M | -1709.00000M |
| Capital expenditures | 2571.00M | 2200.00M | 2606.00M | 2460.00M | 1371.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | 3757.00M | 2021.00M | 361.00M | -346.00000M | -639.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -1930.00000M | -2323.00000M | -2627.00000M | -1995.00000M | -2489.00000M |
| Free cash flow | 7237.00M | 3763.00M | 2193.00M | 509.00M | 1247.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AZNCF AstraZeneca PLC |
2.89 2.06% | 143.15 | 34.63 | 15.72 | 4.52 | 5.46 | 5.12 | 16.91 |
| LLY Eli Lilly and Company |
-21.12 2.64% | 778.22 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
-1.645 1.05% | 155.18 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-6.225 3.25% | 185.29 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
-2.191 2.62% | 81.48 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
| Name | Title | Year Born |
|---|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Exec. Director | 1975 |
| Mr. Marc Dunoyer | CEO of Alexion & Chief Strategy Officer | 1952 |
| Ms. Pam P. Cheng | EVP of Operations & Information Technology and Member of External Sustainability Advisory Board | 1971 |
| Mr. Chris Sheldon | Head of Investor Relations | NA |
| Mr. Jeffrey Pott | Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board | NA |
| Ms. Katarina Ageborg | EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board | NA |
| Gonzalo Vina | Head of Global Media Relations | NA |
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board | 1967 |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...